Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome....
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of RVU.WA is 40 and suggests 52% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell